Precision medicine has changed oncologic practice but is only beginning to be realized for sepsis management. Differing methodologies for precision medicine delivery will be discussed with areas for future development.
Learning Objectives:
Develop next steps in clinical application of current research in pathogen-targeted therapies (toxin-directed or vaccines) and utilization of immune targeting agents (IL-7, GM-CSF, or anti-heme)
Examine current strategies and next-generation targeted therapies to patient immune phenotype in sepsis
Recognize the current state of the science and future directions in the relevance of sepsis immune phenotype and potential diagnostic modalities including monocyte phenotyping with HLA-DR expression and IFN-G production with flow cytometry and ELISPOT
Discuss future directions for current research in immunoadjuvant therapies (checkpoint inhibitors, IL-7, IL-8, IL-10), Pathogen-specific therapies (vaccines, antimicrobials), and immune dysregulation modifying agents as therapeutic targets (anti-heme, anti-hb)
